US20100081685A1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
US20100081685A1
US20100081685A1 US12569057 US56905709A US2010081685A1 US 20100081685 A1 US20100081685 A1 US 20100081685A1 US 12569057 US12569057 US 12569057 US 56905709 A US56905709 A US 56905709A US 2010081685 A1 US2010081685 A1 US 2010081685A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
pharmaceutical composition
composition according
dissolution
formula
dissolution test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12569057
Inventor
Masazumi Kojima
Yoshio Kuno
Hiroaki Nakagami
Shinji Sagasaki
Koichi Ishidoh
Gaku Sekiguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range.
The pharmaceutical composition is characterized by containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive.
Figure US20100081685A1-20100401-C00001

Description

    FIELD OF THE INVENTION
  • The present invention relates to a pharmaceutical composition useful as an anticoagulant, which comprises a component that is improved in dissolution property.
  • BACKGROUND OF THE INVENTION
  • N1-(5-chloropyridin-2-yl)-N2-(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by formula (1), its pharmacologically acceptable salt, and their hydrates (hereinafter referred to as “compound (1)”) are known to have a potent inhibitory action on activated blood coagulation factor X. Compound (1) also is known to be useful as a pharmaceutical, particularly such as an activated blood coagulation factor X inhibitor; a blood coagulation suppresser; an agent for preventing and/or treating thrombosis or embolism; an agent for preventing and/or treating thrombotic diseases; or an agent for preventing and/or treating cerebral infarction, cerebral embolism, heart infarction, angina pectoris, pulmonary embolism, Buerger's disease, deep vein thrombosis, universal intravascular coagulation syndrome, thrombus formation after artificial valve/joint replacement, thrombus formation and reocclusion after revascularization, multiple organ dysfunction syndrome (MODS), or thrombus formation during extracorporeal circulation or blood coagulation upon blood sample collection (Patent Documents 1 to 4).
  • Figure US20100081685A1-20100401-C00002
  • Patent Document 1: WO 03/000657 Patent Document 2: WO 03/000680 Patent Document 3: WO 03/016302 Patent Document 4: WO 2004/058715 DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention
  • In a pharmaceutical composition for oral administration (e.g., tablet), the dissolution property of a pharmaceutically active ingredient thereof has an influential role in the efficacy and safety of the composition. Therefore, each country has established a standard rule pertaining to dissolution test method and its specification. Take Japan, the United States and Europe, for example. These countries are each publishing their Pharmacopoeias in which a method for carrying out a dissolution test is explained for guidance. Under such pharmacopeia, there are a variety of medium that are allowed to use for dissolution test (hereinafter referred to as “dissolution test medium”). These dissolution test medium have a pH that is adjusted to 1 to 8. Examples of the dissolution test medium described in the Pharmacopoeias of many countries include strongly acidic dissolution test medium (e.g., the first fluid for dissolution testing described in the Japanese Pharmacopoeia (hereinafter referred to as “JP 1st fluid”) and 0.1N hydrochloric acid), dissolution test medium having a pH of 3 to 5 (e.g., acetic acid-sodium acetate buffer solution and McIlvaine buffer solution), dissolution test medium having a pH of 6.8 (e.g., the second fluid for dissolution testing described in the Japanese Pharmacopoeia (hereinafter referred to as “JF 2nd fluid”) and phosphate buffer solution having a pH of 6.8), and water. A pharmaceutical drug product for oral administration is required to exhibit sufficient dissolution property when its dissolution test is carried out using such a medium.
  • Meanwhile, Compound (1) is a basic compound and exhibits high solubility in a strong acidic aqueous solution, but its solubility decreases in a neutral pH aqueous solution (e.g., neutral buffer solution). Compound (1) itself exhibits excellent absorbability, if orally administered to a subject. On the other hand, an orally-administered pharmaceutical composition containing Compound (1) that can be produced by use of a commonly used pharmaceutical excipient (e.g., lactose or cornstarch) turned out to have no good dissolution property.
  • Thus, an object of the present invention is to provide a pharmaceutical composition containing Compound (1) as an active ingredient and exhibiting excellent dissolution property.
  • Means for Solving the Problems
  • In view of the foregoing, the present inventors have produced compositions containing Compound (1) with a variety of pharmaceutical excipients, and have investigated the dissolution characteristics of the produced compositions. At last, surprisingly it has been found that the Compound (1) dissolution property of such a composition can be enhanced by incorporating a sugar alcohol and/or a water-swelling additive into the composition, or by coating a composition containing Compound (1) with one or more coating agents selected from among a cellulose derivative, a polyvinyl compound, an acrylate derivative, and a saccharide. The present invention has been accomplished on the basis of this finding.
  • The present invention is thus directed to (1) a pharmaceutical composition comprising (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive.
  • [F2]
  • Figure US20100081685A1-20100401-C00003
  • The present invention is also directed to pharmaceutical compositions as listed below:
  • (2) a pharmaceutical composition as described in (1) above, wherein the sugar alcohol is mannitol, xylitol, or erythritol;
    (3) a pharmaceutical composition as described in (1) above, wherein the sugar alcohol is mannitol;
    (4) a pharmaceutical composition as described in any of (1) to (3) above, wherein the water-swelling additive is pregelatinized starch or crystalline cellulose;
    (5) a pharmaceutical composition as described in any of (1) to (3) above, wherein the water-swelling additive is pregelatinized starch;
    (6) a pharmaceutical composition comprising, as an active ingredient, N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by the aforementioned formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, which composition is coated with at least one coating agent selected from among a cellulose derivative, a polyvinyl compound, an acrylate derivative, and a saccharide;
    (7) a pharmaceutical composition as described in (6) above, wherein the coating agent is one or more species selected from among hypromellose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, povidone, Polyvinyl acetate, polyvinyl acetal diethylaminoacetate, aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer dispersion, sucrose, and mannitol;
    (8) a pharmaceutical composition as described in (6) above, wherein the coating agent is one or more species selected from among a cellulose derivative and a polyvinyl compound;
    (9) a pharmaceutical composition as described in (6) above, wherein the coating agent is one or more species selected from among hypromellose, ethyl cellulose, and polyvinyl alcohol;
    (10) a pharmaceutical composition as described in (6) above, wherein the coating agent is hypromellose;
    (11) a pharmaceutical composition as described in any one of (1) to (5) above, which is coated with at least one coating agent selected from among a cellulose derivative, a polyvinyl compound, a acrylate derivative, and saccharide;
    (12) a pharmaceutical composition as described in (11) above, wherein the coating agent is one or more species selected from among hypromellose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, povidone, Polyvinyl acetate, polyvinyl acetal diethylaminoacetate, aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer dispersion, sucrose, and mannitol;
    (13) a pharmaceutical composition as described in (11) above, wherein the coating agent is one or more species selected from among a cellulose derivative and a polyvinyl compound;
    (14) a pharmaceutical composition as described in (11) above, wherein the coating agent is one or more species selected from among hypromellose, ethyl cellulose, and polyvinyl alcohol;
    (15) a pharmaceutical composition as described in (11) above, wherein the coating agent is hypromellose;
    (16) a pharmaceutical composition as described in any one of (6) to (15) above, wherein the coating agent is contained in an amount of 0.5 to 20 wt. % with respect to the total weight of the pharmaceutical composition;
    (17) a pharmaceutical composition as described in any one of (1) to (16) above, wherein the compound represented by formula (1) is N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide hydrochloride;
    (18) a pharmaceutical composition as described in any one of (1) to (15) above, wherein the compound represented by formula (1) is N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate;
    (19) a pharmaceutical composition as described in any one of (1) to (18) above, which has a dosage form of oral preparation;
    (20) a pharmaceutical composition as described in any one of (1) to (19) above, which has a dosage form of solid preparation;
    (21) a pharmaceutical composition as described in any one of (1) to (20) above, which has a dosage form of tablet, capsule, granule, or powder;
    (22) a pharmaceutical composition as described in any one of (1) to (20) above, which has a dosage form of tablet;
    (23) a pharmaceutical composition as described in any one of (1) to (22) above, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 6.8, of 60% or higher in 30 minutes after the start of the dissolution test and 70% or higher in 60 minutes after the start;
    (24) a pharmaceutical composition as described in any one of (1) to (22) above, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 6.8, of 70% or higher in 30 minutes after the start of the dissolution test and 80% or higher in 60 minutes after the start;
    (25) a pharmaceutical composition as described in any one of (1) to (24) above, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 4.5, of 85% or higher in 30 minutes after the start of the dissolution test;
    (26) a method for enhancing dissolution rate of a compound represented by formula (1), the method employing a pharmaceutical composition as recited in (1) to (25); and
    (27) a pharmaceutical composition as described in (1) to (25) above, wherein dissolution rate of the compound represented by formula (1) serving as an active ingredient is enhanced.
  • ADVANTAGEOUS EFFECT OF THE INVENTION
  • The present invention has made it possible to obtain a pharmaceutical composition for oral administration, which contains Compound (1) and exhibits consistent dissolution characteristics while falling within the pH range of the aforementioned dissolution test medium. Thus the present invention provides an oral anticoagulant containing compound (1) as a pharmaceutically active ingredient and exhibiting favorable dissolution characteristics can be provided.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 A graph showing dissolution properties of tablets having formulations A to E (dissolution test medium: acetate buffer solution (pH 4.0)).
  • FIG. 2 A graph showing dissolution properties of tablets having formulations F to I (dissolution test medium: acetate buffer solution (pH 4.0)).
  • FIG. 3 A graph showing dissolution properties of tablets having formulations J to N (dissolution test medium: 0.1N hydrochloric acid).
  • FIG. 4 A graph showing dissolution properties of tablets having formulations J to N (dissolution test medium: water).
  • FIG. 5 A graph showing dissolution properties of tablets having formulations J to N (dissolution test medium: phosphate buffer solution (pH 6.8)).
  • FIG. 6 A graph showing dissolution properties of tablets coated with hypromellose (dissolution test medium: phosphate buffer solution (pH 6.8)).
  • FIG. 7 A graph showing dissolution properties of tablets coated with various coating agents (dissolution test medium: phosphate buffer solution (pH 6.8)).
  • FIG. 8 A graph showing dissolution properties of tablets coated with hypromellose (dissolution test medium: acetate buffer solutions (pH 4.0) and (pH 4.5)).
  • BEST MODES FOR CARRYING OUT THE INVENTION
  • The compound represented by formula (1) may be a hydrate of the compound, a pharmacologically acceptable salt of the compound, or a hydrate of the salt.
  • Examples of the salt of the compound represented by formula (1) include hydrochloride, sulfate, hydrobromide, hydroiodide, phosphate, nitrate, benzoate, methanesulfonate, 2-hydroxyethanesulfonate, p-toluenesulfonate, acetate, propanoate, oxalate, malonate, succinate, glutarate, adipate, tartrate, maleate, fumarate, malate, and mandelate.
  • Examples of preferred salts of the compound represented by formula (1) include hydrochloride, methanesulfonate, and p-toluenesulfonate. Of these, p-toluenesulfonate is particularly preferred.
  • Examples of the preferred compounds represented by formula (1) include the following ones:
    • N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide;
    • N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide hydrochloride;
    • N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate; and
  • N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate (compound (1a), which is represented by the following formula (1a).
  • [F3]
  • Figure US20100081685A1-20100401-C00004
  • These compounds (1) may be produced by the methods disclosed in Patent Documents 1 to 4 or their analogic methods.
  • As one of the characteristics of the present invention, it can be said that when incorporated into a solid preparation, a coating agent serves to accelerate the dissolution of Compound (1), which is a pharmaceutically active ingredient, from a solid preparation containing Compound (1). In other words, the present invention provides a pharmaceutical composition for oral administration containing Compound (1) and a coating agent, and exhibiting excellent dissolution property. No particular limitation is imposed on the form of the pharmaceutical composition for oral administration of the present invention containing Compound (1) and a coating agent. The pharmaceutical composition of the invention encompasses not only coated solid preparations such as tablets but also various solid preparations containing a coating agent. As an example of such solid preparations containing Compound (1), a coating agent forms a matrix in the solid preparation.
  • In the pharmaceutical composition for oral administration, examples of the coating agent employed for enhancing dissolution rate of Compound (1) include coating agents generally employed in pharmaceutical manufacturing for coating tablets and granules therewith. Preferably, the coating agent has low solubility within a pH range in the intestine. Specifically, a coating agent which is difficult to dissolve within the pH range in the intestine is generally preferred, as compared with an enteric coating agent.
  • Specific examples of preferred coating agents include the following:
  • (1) cellulose derivatives such as hypromellose (hydroxypropyl methylcellulose), hydroxypropyl cellulose, ethyl cellulose, and methyl cellulose;
  • (2) polyvinyl compounds such as polyvinyl alcohol, povidone (polyvinylpyrrolidone), polyvinyl acetal diethylaminoacetate, and Polyvinyl acetate;
  • (3) acrylate derivatives such as aminoalkyl methacrylate copolymer RS and ethyl acrylate-methyl methacrylate copolymer dispersion; and
  • (4) saccharides (including sugar alcohols) such as sucrose and mannitol, which are used as sugar-coating agents. These coating agents may be used singly or in combination or two or more species. Hypromellose or a hypromellose-based coating agent includes species such as hypromellose 2208, hypromellose 2906, and hypromellose 2910 having different viscosities (mPa·s). These species having different viscosities may be used singly or in combination of two or more species.
  • Among these, preferred are one or more species selected from the group consisting of cellulose derivatives (hypromellose, methyl cellulose, ethyl cellulose and hydroxypropyl cellulose); polyvinyl compounds (polyvinyl alcohol, povidone, Polyvinyl acetate and polyvinyl acetal diethylaminoacetate); acrylate derivatives (amino alkyl methacrylate copolymer RS and ethyl acrylate-methyl methacrylate copolymer dispersion); and saccharides (including sugar alcohols) (sucrose and mannitol).
  • Of these, one or more species selected from among cellulose derivatives and polyvinyl compounds are more preferred. Still more preferred are one or more species selected from among hypromellose, ethyl cellulose, and polyvinyl alcohol. Among them, hypromellose is particularly preferred.
  • In the present invention, the aforementioned coating agent and other additives required for preparing coating suspension (e.g., a plasticizer) may be incorporated in combination into the composition. Examples of the additives required for preparing coating suspension (e.g., a plasticizer) include Macrogols (polyethylene glycols having an av. weight molecular weight of 1,000 to 35,000) such as Macrogol 1000, Macrogol 1500, Macrogol 1540, Macrogol 4000, Macrogol 6000, Macrogol 8000, Macrogol 20000, and Macrogol 35000; glycerin fatty acid esters; sucrose fatty acid esters; castor oil; triethyl citrate; triacetin; and talc. The aforementioned coating agents may further contain the below-mentioned coloring agent, and the mixture may be incorporated into the pharmaceutical composition of the present invention.
  • From the viewpoint of enhancing dissolution rate of Compound (1), the pharmaceutical composition of the present invention preferably contains a coating agent in an amount of 0.5 to 20 wt. %, more preferably 1 to 15 wt. %, particularly preferably 1.5 to 10 wt. %.
  • Next will be described coating of a solid preparation, which is a typical embodiment of the present invention.
  • In the present invention, a solid preparation containing Compound (1) may be coated with the aforementioned coating agent through a widely known coating process for solid preparation coating. No particular limitation is imposed cn the coating process, and for example, there may be employed a spray coating process in which a solution/dispersion of the coating agent is sprayed onto a solid preparation containing Compound (1) by means of a fluidized bed coater or a pan coater; an dip coating process in which a solid preparation containing Compound (1) is dipped in a coating suspension; and a dry coating process employing impact in a gas flow. The solid preparation containing Compound (1) which has not been subjected to the coating process may be produced through a conventionally known process.
  • Thus, the pharmaceutical composition of the present invention may be produced by preparing a solid preparation containing Compound (1) as a pharmaceutically active ingredient through a known method and then coating the thus-prepared solid preparation with a coating agent.
  • No particular limitation is imposed on the solid preparation containing Compound (1) which has not been subjected to the coating process. However, preferred embodiments will next be described.
  • When a solid preparation containing Compound (1) was produced by use of a combination of lactose and cornstarch, which is a combination of diluents generally employed in the production of solid preparations such as tablets, the produced solid preparation exhibited unsatisfactory dissolution characteristics in the dissolution tests using a strong acidic test medium, a test medium having a pH of 3 to 5, and water. In contrast, a solid preparation (1) containing compound (1) with sugar alcohol, and a solid preparation (2) containing Compound (1) and a water-swelling additive have exhibited improved dissolution properties, as compared with those of a solid preparation containing Compound (1) with lactose and cornstarch. Furthermore, a solid preparation (3) containing Compound (1) and produced by use of sugar alcohol and a water-swelling additive in combination have exhibited satisfactory dissolution characteristics in the dissolution tests using a strong acidic test medium, a test medium having a pH of 3 to 5, and water.
  • Therefore, other preferred embodiments of the solid preparation containing Compound (1) which has not been subjected to the coating process and which is employed in the present invention include the following: a solid preparation (1) containing compound (1) and sugar alcohol; a solid preparation (2) containing Compound (1) and a water-swelling additive; and a solid preparation (3) containing Compound (1) with sugar alcohol and a water-swelling additive. Of these, a solid preparation (3) containing Compound (1) with sugar alcohol and a water-swelling additive is more preferred.
  • The water-swelling additive employed in the present invention refers to an additive for pharmaceuticals which swells with water added thereto. Examples of the water-swelling additive in the present invention include diluents and bases, which are water-swellability. Specific examples of the water-swelling additive include pregelatinized starch, α-starch, crystalline cellulose, sodium starch glycolate, carmellose (carboxymethyl cellulose), carmellose calcium, croscarmellose sodium (croscarboxymethyl cellulose sodium), soybean lecithin, low-substituted hydroxypropyl cellulose, Powdered tragacanth, and bentonite. These additives may be used singly or in combination of two or more species.
  • Among these water-swelling additives, pregelatinized starch and crystalline cellulose are preferred, with pregelatinized starch being more preferred. As crystalline cellulose, Ceolus (product of Asahi Chemical Industry Co., Ltd.) is particularly preferred. As pregelatinized starch, PCS (product of Asahi Chemical Industry Co., Ltd.) and Starch 1500 (product of Colorcon Japan Limited) are particularly preferred.
  • Examples of preferred sugar alcohols which can improve dissolution of Compound (1) include mannitol, erythritol, and xylitol. Of these, mannitol is particularly preferred.
  • To the composition of the present invention, a water-soluble diluent other than sugar alcohol may be added. Examples of the water-soluble diluent include fructose, purified sucrose, sucrose, purified sucrose spherical granules, lactose, anhydrous lactose, sucrose•starch spherical granules, semi-digested starch, glucose, glucose hydrate, powdered sugar, pullulan, and β-cyclodextrin. Other than saccharides, examples further include aminoethylsulfonic acid, maltose syrup powder, sodium chloride, citric acid, sodium citrate, glycine, calcium gluconate, L-glutamine, tartaric acid, potassium hydrogentartrate, ammonium carbonate, dextran 40, dextrin, calcium lactate, povidone, Macrogol (polyethylene glycol) 1500, Macrogol 1540, Macrogol 4000, Macrogol 6000, anhydrous citric, DL-malic acid, sodium hydrogenphosphate, potassium dihydrogenphosphate, and sodium dihydrogenphosphate.
  • The water-soluble diluent is preferably selected from saccharides. Specific examples include purified sucrose, sucrose, lactose, lactose granules, glucose, glucose hydrate, powdered sugar, and pullulan. Of these, lactose is more preferred.
  • From the viewpoint of improvement of dissolution of Compound (1), the solid preparation containing Compound (1) preferably contains a sugar alcohol in an amount of 0.01 to 99.0 wt. %, more preferably 20 to 80 wt. %, particularly preferably 40 to 60 wt. %. Also, the solid preparation containing Compound (1) preferably contains a water-swelling additive in an amount of 0.01 to 90 wt. %, more preferably 0.1 to 80 wt. %, particularly preferably 5 to 50 wt. %.
  • In the case where the solid preparation contains the aforementioned water-swelling additive and sugar alcohol, the ratio of water-swelling additive to sugar alcohol in the preparation is preferably 0.05 to 50 parts by weight (sugar alcohol) to 1 part by weight (water-swelling additive), more preferably 1 to 10 parts by weight (sugar alcohol), particularly preferably 1.5 to 4 parts by weight (sugar alcohol).
  • In addition to the combination of the aforementioned sugar alcohol and water-swelling additive, the pharmaceutical composition containing Compound (1) may further contain a water-insoluble diluent, a disintegrant, a binder, a fluidizing agent, a lubricant, a coloring agent, a polishing agent, etc., so long as the effect of the present invention is not impaired.
  • Examples of the water-insoluble diluent include L-aspartic acid, alginic acid, carmellose sodium, hydrous silicon dioxide, crospovidone, calcium glycerophosphate, magnesium silicate aluminate, calcium silicate, magnesium silicate, light anhydrous silicic acid, crystalline cellulose, cellulose powder, synthetic aluminum silicate, synthetic aluminum silicate•hydroxypropyl starch•crystalline cellulose, flour, wheat starch, wheat germ powder, wheat germ oil, rice powder, rice starch, cellulose acetate phthalate, titanium oxide, magnesium oxide, dihydroxyaluminum aminoacetate, calcium tertiary phosphate, talc, calcium carbonate, magnesium carbonate, precipitated calcium carbonate, natural aluminum silicate, cornstarch, granulated cornstarch, potato starch, hydroxypropyl cellulose, hydroxypropyl starch, calcium hydrogenphosphate anhydrous, granulated calcium hydrogenphosphate anhydrous, and calcium dihydrogenphosphate. Of these, crystalline cellulose and cellulose powder are preferred as a water-insoluble diluent.
  • Examples of the disintegrant include adipic acid, alginic acid, α-starch, sodium starch glycolate, carmellose, carmellose calcium, carmellose sodium, hydrous silicon dioxide, calcium citrate, croscarmellose sodium, crospovidone, light anhydrous silicic acid, crystalline cellulose, synthetic aluminum silicate, wheat starch, rice starch, cellulose acetate phthalate, calcium stearate, low-substituted hydroxypropyl cellulose, cornstarch, powdered tragacanth, potato starch, hydroxyethylmethyl cellulose, hydroxypropyl starch, pregelatinized starch, monosodium fumarate, povidone, anhydrous citric, methyl cellulose, and calcium dihydrogenphosphate. Of these, crospovidone and sodium starch glycolate are preferred as a disintegrant.
  • Examples of the binder include maltose syrup powder, gum arabic, gum arabic powder, sodium alginate, propylene glycol alginate ester, hydrolyzed gelatin powder, hydrolyzed starch-light anhydrous silicic acid, fructose, carboxylvinyl polymer, carboxymethylethyl cellulose, hydrous silicon dioxide, agar powder, light anhydrous silicic acid, light anhydrous silicic acid-containing hydroxypropyl cellulose, crystalline cellulose, synthetic aluminum silicate, high-molecule polyvinylpyrrolidone, copolydone, flour, wheat starch, rice powder, rice starch, Polyvinyl acetate, cellulose acetate phthalate, dioctyl sodium sulfosuccinate, dihydroxyaluminum aminoacetate, sodium potassium tartrate, water, sucrose fatty acid ester, purified gelatin, purified sucrose, gelatin, D-sorbitol, dextrin, starch, cornstarch, tragacanth, powdered tragacanth, lactose, concentrate glycerin, sucrose, potato starch, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hydroxypropylmethyl cellulose 2208, hydroxypropylmethyl cellulose 2906, hydroxypropylmethyl cellulose 2910, hydroxypropylmethyl cellulose phthalate, vinylpyrrolidone-vinyl acetate copolymer, piperonyl butoxide, glucose, pregelatinized starch, fumaric acid, fumaric acid-stearic acid•polyvinyl acetal diethylaminoacetate•hydroxypropylmethyl cellulose 2910 mixture, pullulan, povidone, polyvinyl alcohol (completely saponified product), polyvinyl alcohol (partially saponified product), sodium polyphosphate, Macrogol 4000, Macrogol 6000, Macrogol 20000, D-mannitol, and methyl cellulose.
  • Examples of the fluidizing agent include hydrous silicon dioxide, light anhydrous silicic acid, crystalline cellulose, synthetic aluminum silicate, titanium oxide, stearic acid, calcium stearate, magnesium stearate, calcium tertiary phosphate, talc, cornstarch, and magnesium metasilicate aluminate.
  • Examples of the lubricant include cacao fat, carnauba wax, hydrous silicon dioxide, dry aluminum hydroxide gel, glycerin fatty acid ester, magnesium silicate, light anhydrous silicic acid, crystalline cellulose, hardened oil, synthetic aluminum silicate, white beeswax, magnesium oxide, sodium potassium tartrate, sucrose fatty acid ester, stearic acid, calcium stearate, magnesium stearate, stearyl alcohol, polyoxyl 40 stearate, cetanol, soybean hardened oil, gelatin, talc, magnesium carbonate, precipitated calcium carbonate, cornstarch, potato starch, fumaric acid, stearyl sodium fumarate, Macrogol 600, Macrogol 4000, Macrogol 6000, beeswax, magnesium metasilicate aluminate, sodium laurate, and magnesium sulfate.
  • Examples of the coloring agent include yellow iron sesquioxide, iron sesquioxide, titanium oxide, orange essence, brown iron oxide, β-carotene, black iron oxide, Food Blue No. 1, Food Blue No. 2, Food Red No. 2, Food Red No. 3, Food Red No. 102, Food yellow No. 4, and Food yellow No. 5.
  • Examples of the polishing agent include carnauba wax, hardened oil, Polyvinyl acetate, white beeswax, titanium oxide, stearic acid, calcium stearate, polyoxyl 40 stearate, magnesium stearate, purified shellac, purified paraffin•carnauba wax mixture, cetanol, talc, colored silver foil, white shellac, paraffin, povidone, Macrogol 1500, Macrogol 4000, Macrogol 6000, beeswax, glycerin monostearate, and rosin. Of these, carnauba wax, titanium oxide, and talc are preferred as a polishing agent.
  • No particular limitation is imposed on the dosage form of the pharmaceutical composition of the present invention, so long as the drug preparation thereof can be orally administered to a subject. However, the dosage form is preferably a solid preparation, specifically in the form of tablet, granules, powder (including fine granules), or capsule. The solid preparation may be produced through a widely known production method therefor. In one exemplified procedure, the pharmaceutical composition of the present invention is prepared through mixing the aforementioned Compound (1), a sugar alcohol and/or a water-swelling additive, and optional additives such as a disintegrant, a binder, a fluidizing agent, a lubricant, a coloring agent, and a polishing agent, and the mixture is processed through, for example, the method of producing solid preparations described in the general rules for preparations in the Japanese Pharmacopoeia.
  • When the pharmaceutical composition of the present invention is in the dosage form of granules, the granules may be produced through blending Compound (1) with a sugar alcohol and/or a water-swelling additive and optional additives such as a diluent, a binder, a disintegrant, and other appropriate members, and granulating the thus-obtained uniform mixture through an appropriate technique. Additionally, the thus-produced granules may be coated with a coating agent by means of a fluidized bed coater through spraying a suspension/solution of the coating agent onto the granules.
  • When the pharmaceutical composition of the present invention is in the dosage form of powder, the powder (or microgranules) may be produced through blending Compound (1) with a sugar alcohol and/or a water-swelling additive and optional additives such as a diluent, a binder, a disintegrant, and other appropriate members, to thereby form a uniform admixture, and pulverizing or micro-granulating the thus-obtained admixture through an appropriate technique. Additionally, the thus-produced powder (or microgranules) granules may be coated with a coating agent by means of a fluidized bed coater through spraying a suspension/solution of the coating agent onto the powder (or microgranules).
  • When the pharmaceutical composition of the present invention is in the dosage form of capsule, the aforementioned granules or powder may be encapsulated with coating capsules.
  • When the pharmaceutical composition of the present invention is in the dosage form of tablet, tablets may be produced directly through compression molding of a powder mixture containing the aforementioned Compound (1) and acceptable additives for pharmaceuticals, preferably a powder mixture containing the aforementioned Compound (1), a sugar alcohol and/or a water-swelling additive, and acceptable additives for pharmaceuticals. Alternatively, the tablets may be produced through granulating a powder mixture containing the aforementioned Compound (1) and acceptable additives for pharmaceuticals, preferably a powder mixture containing the aforementioned Compound (1), a sugar alcohol and/or a water-swelling additive, and acceptable additives for pharmaceuticals, through a technique such as fluidized bed granulation or agitation granulation, followed by compression molding of the formed granules. The pressure of compression molding may be determined within an appropriate range, so long as the effect of the present invention is not impaired. The compression molding is preferably performed at 6 to 15 kN. No particular limitation is imposed on the shape of the tablets, and lens-shape, disk-shape, round, oval, triangle, and polygon shapes such as lozenges are preferred. Additionally, the thus-produced tablets may be further coated with a coating agent by means of a pan coater through spraying a suspension/solution of the coating agent onto the tablets.
  • The pharmaceutical composition of the present invention generally has a Compound (1) content of 10 to 30 wt. % (as free form), preferably 12 to 25 wt. %. Particularly when the pharmaceutical composition of the present invention is in the table form, the Compound (1) content (as free form) is generally 1 to 100 mg/tablet, preferably 5 to 75 mg/tablet, more preferably 15 to 60 mg/tablet.
  • The Compound (1) dissolution property of the pharmaceutical composition of the present invention can be evaluated by, for example, dissolution tests disclosed in the Japanese Pharmacopoeia, the United States Pharmacopoeia (USP), and the European Pharmacopoeia. Examples of the test medium employed in the dissolution tests will next be described.
  • Non-limitative examples of the aforementioned strongly acidic dissolution test medium include the JP 1st fluid described in the Japanese Pharmacopoeia, and “USP 0.1N HCl, Simulated Gastric Fluid without Enzyme” described in the United States Pharmacopoeia.
  • Non-limitative examples of the dissolution test medium (pH: 6.8) include the JP 2nd fluid and phosphate buffer (pH: 6.8) described in the Japanese Pharmacopoeia; “USP Phosphate Buffer (pH: 6.8), Simulated Intestinal Fluid without Enzyme” described in the United States Pharmacopoeia; and Phosphate Buffer Solution (pH: 6.8) described in the European Pharmacopoeia.
  • The dissolution test medium (pH: 3 to 5) may be a test medium having a pH of 4.0 or 4.5. Specific examples include acetic acid-sodium acetate buffer described in the Japanese Pharmacopoeia; “USP Acetate Buffer” described in the United States Pharmacopoeia; and Acetate Buffer Solution (pH: 4.5) described in the European Pharmacopoeia. Alternatively, a diluted McIlvaine buffer (pH: 4.0) may also be employed.
  • However, the dissolution test medium (pH: 3 to 5) is not limited to the above examples.
  • These dissolution test medium are prepared through methods described in the corresponding Pharmacopoeia. When the employed dissolution test medium is a buffer solution, variation of the pH of the test medium specified in the corresponding Pharmacopoeia is preferably controlled to fall within a range of ±0.05.
  • When the composition is subjected to the dissolution test disclosed in the Japanese Pharmacopoeia (paddle method; at a rotation rate of 50 rpm), the composition preferably exhibit an average percent dissolution of Compound (1), in a dissolution test medium having a pH of 6.8, of 60% or higher in 30 minutes after the start of the dissolution test and 70% or higher in 60 minutes after the start, more preferably 70% or higher in 30 minutes after the start and 80% or higher in 60 minutes after the start.
  • When the composition is subjected to the dissolution test disclosed in the Japanese Pharmacopoeia (paddle method; at a rotation rate of 50 rpm), the composition preferably exhibit an average percent dissolution of Compound (1), in a dissolution test medium having a pH of 4.5, of 85% or higher in 30 minutes after the start of the dissolution test.
  • As used herein, the “average percent dissolution” refers to an average of percent dissolution values obtained from at least 3, preferably 6, more preferably 12 solid preparation samples of a single type.
  • EXAMPLES
  • The present invention will next be described in detail by way of examples, which should not be construed as limiting the invention thereto.
  • Example 1 Effect of Diluent
  • Tablets containing compound 1a were produced according to the formulations shown in Table 1 (all values in the table are on “mg” basis). The tablets were analyzed in terms of dissolution of compound 1a in accordance with the method 2 (paddle method) at a rotation rate of 50 rpm described in the Japanese Pharmacopoeia. Percent dissolution was calculated by averaging percent dissolution values of three tablets of the same formulation. An acetate buffer (pH: 4.0) was employed as a dissolution test medium. The acetate buffer (pH: 4.0) was prepared through the following procedure.
  • Method for preparing the acetate buffer (pH: 4.0): Sodium acetate trihydrate (2.45 g) and glacial acetic acid (4.9 g) were weighed, and purified water was added thereto, so that the total volume of the buffer came to 1,000 mL.
  • (Preparation of Tablets)
  • In each case, ingredients shown in Table 1 excepting hydroxypropyl cellulose and magnesium stearate were mixed by means of a mortar, and the mixture was granulated by use of aqueous hydroxypropyl cellulose solution. The thus-produced granules were mixed with magnesium stearate, to thereby yield granules were compressed into tablets using 8.0 mmφ round shaped dies and punches at 7.8 kN of compression force, to thereby yield tablets of interest. In Example 1, the following materials were employed as the ingredients listed in Table 1.
  • Lactose [Pharmatose 200M (trade name)], mannitol [Mannit (trade name)], cornstarch [Cornstarch (trade name)], crystalline cellulose [Ceolus (trade name)], pregelatinized starch [PCS (trade name)], sodium starch glycolate [Primojel (trade name)], hydroxypropyl cellulose [HPC-L (trade name)], and magnesium stearate [HyQual (trade name)].
  • TABLE 1
    Formulation (mg) A B C D E
    Compound 1a 40.41 40.41 40.41 40.41 40.41
    Lactose 99.79 99.79
    Mannitol 99.79 99.79 99.79
    Cornstarch 42.8 42.8
    Crystalline cellulose 42.8
    Pregelatinized starch 42.8 42.8
    Sodium starch glycolate 10.0 10.0 10.0 10.0 10.0
    Hydroxypropyl cellulose 6.0 6.0 6.0 6.0 6.0
    Mg stearate 1.0 1.0 1.0 1.0 1.0
    Weight/tablet 200.0 mg 200.0 mg 200.0 mg 200.0 mg 200.0 mg
  • FIG. 1 shows the results of the dissolution test (in acetate buffer solution (pH: 4.0)) of the tablets of formulations A to E in Table 1. As is clear from FIG. 1, tablets containing mannitol as a diluent (formulation B), those containing pregelatinized starch as a diluent (formulations C and D), and those containing crystalline cellulose as a diluent (formulation E) exhibited excellent compound 1a dissolution characteristics. Tablets containing mannitol and pregelatinized starch as a diluent (formulation D) and those containing mannitol and crystalline cellulose as a diluent (formulation E) exhibited more excellent compound 1a dissolution characteristics. In contrast, when lactose and cornstarch, which are generally employed as diluent, were employed (formulation A), the compound 1a dissolution property was unsatisfactory.
  • Example 2 Studies on Disintegrant
  • Ingredients shown in Table 2 (all values in the table are on “mg” basis) excepting hydroxypropyl cellulose and magnesium stearate were mixed by means of a mortar, and the mixture was granulated by use of aqueous hydroxypropyl cellulose solution. The thus-produced granules were mixed with magnesium stearate, to thereby yield granules were compressed into tablets using 8.0 mmφ round shaped dies and punches at 7.8 kN of compression force, to thereby yield tablets of interest.
  • In a manner similar to that of Example 1, the produced tables were analyzed in terms of dissolution property. The percent dissolution was calculated by averaging percent dissolution values of three tablet samples.
  • In Example 2, the following disintegrants were employed and compared with one another.
  • Sodium starch glycolate [Primojel (trade name)], crospovidone [Polyplasdone (trade name)], carmellose calcium [ECG-505 (trade name)], and low-substituted hydroxypropyl cellulose [L-HPC (trade name)].
  • TABLE 2
    Formulation (mg) F G H I
    Compound 1a 40.41 40.41 40.41 40.41
    Mannitol 102.59 102.59 102.59 102.59
    Pregelatinized starch 40.0 40.0 40.0 40.0
    Sodiuml starch glycolate 10.0
    Crospovidone 10.0
    Carmellose Ca 10.0
    Low-substituted 10.0
    hydroxypropyl cellulose
    Hydroxypropyl cellulose 6.0 6.0 6.0 6.0
    Mg stearate 1.0 1.0 1.0 1.0
    Weight/tablet 200.0 mg 200.0 mg 200.0 mg 200.0 mg
  • FIG. 2 shows the results of the dissolution test (in acetate buffer solution (pH: 4.0)) of the tablets of formulations F to I in Table 2. As is clear from FIG. 2, tablets containing sodium starch glycolate or crospovidone as a disintegrant exhibited an excellent compound 1a dissolution property.
  • Example 3
  • Tablets containing compound 1a were produced according to the formulations shown in Table 3 (all values in the table are on “mg” basis), and were analyzed in terms of dissolution of compound 1a in a manner similar to that of Example 1, except that 0.1N hydrochloric acid (USP 0.1N HCl), water, and phosphate buffer solution (pH: 6.8) [USP Phosphate buffer solution (pH: 6.8)] were employed as dissolution test medium. In each tablet production, ingredients shown in Table 3 excepting hydroxypropyl cellulose and magnesium stearate were mixed together, and the mixture was granulated by means of a fluidized bed granulator through spraying aqueous hydroxypropyl cellulose solution onto the mixture. The thus-produced granules were mixed with magnesium stearate, to thereby yield granules were compressed into tablets using 8.5 mmφ round shaped dies and punches at 7.5 kN of compression force, to thereby yield tablets of interest. The percent dissolution was calculated by averaging percent dissolution values of six tablet samples.
  • TABLE 3
    Formulation J K L M N
    Compound 1a 40.4 40.4 40.4 40.4 40.4
    Lactose 99.2 99.2
    Mannitol 99.2 99.2 99.2
    Cornstarch 42.0 42.0
    Crystalline cellulose 42.0
    Pregelatinized starch 42.0 42.0
    Crospovidone 10.7 10.7 10.7 10.7 10.7
    Hydroxypropyl cellulose 6.1 6.1 6.1 6.1 6.1
    Mg stearate 1.6 1.6 1.6 1.6 1.6
    Weight/tablet 200.0 mg 200.0 mg 200.0 mg 200.0 mg 200.0 mg
  • FIGS. 3 to 5 show the results of the dissolution test (in 0.1N hydrochloric acid, in water, and in phosphate buffer solution (pH: 6.8)) of the tablets of formulations J to N in Table 3. As is clear from FIGS. 3 to 5, tablets containing mannitol and pregelatinized starch exhibited an excellent compound 1a dissolution property in 0.1N hydrochloric acid and in water.
  • Example 4 Studies on Coating Agent
  • Ingredients shown in Table 4 (all values in the table are on “mg” basis) excepting hydroxypropyl cellulose and magnesium stearate were mixed together, and the mixture was granulated by means of a fluidized bed granulator through spraying aqueous hydroxypropyl cellulose solution onto the mixture. The thus-produced granules were mixed with magnesium stearate, to thereby yield granules were compressed into tablets using 8.5 mmφ round shaped dies and punches at about 10 kN of compression force, to thereby yield tablets of interest. The tables were coated with a commercial coating agent by means of a pan coater (Hicoater Multi, product of Freund Corporation), to thereby prepare film-coated tablets. As the coating agent, a pre-mixed product [OPADRY 03F42132 (trade name)], predominantly containing hypromellose, was used. In a manner similar to that of Example 1, tablets coated with OPADRY 03F42132 (3 mg), those coated with OPADRY 03F42132 (10 mg), and those not coated (non-coated tablets) were subjected to dissolution tests in phosphate buffer solution (pH: 6.8) [USP Phosphate buffer solution (pH: 6.8)]. The results are shown in FIG. 6. The percent dissolution was calculated by averaging percent dissolution values of six tablet samples.
  • Separately, by means of a pan coater (Hicoater Mini, product of Freund Corporation), film-coated tablets were produced through coating non-coated tablets with a coating agent [OPADRY 03F42132 (trade name)] predominantly containing hypromellose, generally employed as a rapidly soluble coating agent; a coating agent [OPADRY AMB (trade name)], predominantly containing polyvinyl alcohol, generally employed as a rapidly soluble coating agent; a coating agent [Aquacoat-ECD (trade name)], predominantly containing ethyl cellulose, serving as a pH-independent sustained-release-type coating agent; or a coating agent [Eudragit L30-D55 (trade name)], predominantly containing methacrylate copolymer LD, serving as a pH-dependent enteric coating agent, the amount coating agent in each case being 10 mg. In a manner similar to that of Example 1, these film-coated tablets were subjected to dissolution tests in phosphate buffer solution (pH: 6.8) [USP Phosphate buffer solution (pH: 6.8)]. The results are shown in FIG. 7. The percent dissolution was calculated by averaging percent dissolution values of six tablet samples.
  • Further, by means of a pan coater (Hicoater Multi, product of Freund Corporation), film-coated tablets were produced through coating non-coated tablets with a coating suspension (10 mg) containing about 60% of hypromellose [TC-5 (trade name)]. In a manner similar to that of Example 1, these film-coated tablets were subjected to dissolution tests in acetate buffer solutions (pH: 4.0) and (pH: 4.5). The results are shown in FIG. 8. The percent dissolution was calculated by averaging percent dissolution values of six tablet samples.
  • TABLE 4
    Ingredients (mg) Formulation
    Compound 1a 40.4
    Mannitol 99.2
    Pregelatinized starch 42.0
    Crospovidone 10.7
    Hydroxypropyl cellulose 6.1
    Mg stearate 1.6
    Weight/tablet 200.0 mg
  • As is clear from FIG. 6, quite surprisingly, tablets coated with a hypromellose-based agent exhibited an improved compound 1a dissolution property at a pH of 6.8, as compared with non-coated tablets. Furthermore, the amount of coating agent did not affect the dissolution behavior.
  • As is clear from FIG. 7, tablets coated with a coating agent other than an enteric coating agent exhibited a considerably excellent dissolution property.
  • As is clear from FIG. 8, tablets coated with a hypromellose-based agent exhibited an equivalently excellent dissolution property in acetate buffer solution (pH: 4.0) and in acetate buffer solution (pH: 4.5).

Claims (38)

  1. 1. A pharmaceutical composition comprising (A) N1-(5-chloropyridin-2-yl)—N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by formula (1):
    Figure US20100081685A1-20100401-C00005
    a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive.
  2. 2. A pharmaceutical composition according to claim 1, wherein the sugar alcohol is mannitol, xylitol, or erythritol.
  3. 3. A pharmaceutical composition according to claim 1, wherein the sugar alcohol is mannitol.
  4. 4. A pharmaceutical composition according to claim 1, wherein the water-swelling additive is pregelatinized starch or crystalline cellulose.
  5. 5. A pharmaceutical composition according to claim 1, wherein the water-swelling additive is pregelatinized starch.
  6. 6. A pharmaceutical composition comprising, as an active ingredient, N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by formula (1):
    Figure US20100081685A1-20100401-C00006
    a pharmacologically acceptable salt thereof, or a hydrate of any of these, which composition is coated with at least one coating agent selected from among a cellulose derivative, a polyvinyl compound, an acrylate derivative, and a saccharide.
  7. 7. A pharmaceutical composition according to claim 6, wherein the coating agent is one or more species selected from among hypromellose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, povidone, Polyvinyl acetate, polyvinyl acetal diethylaminoacetate, aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer dispersion, sucrose, and mannitol.
  8. 8. A pharmaceutical composition according to claim 6, wherein the coating agent is one or more species selected from among a cellulose derivative and a polyvinyl compound.
  9. 9. A pharmaceutical composition according to claim 6, wherein the coating agent is one or more species selected from among hypromellose, ethyl cellulose, and polyvinyl alcohol.
  10. 10. A pharmaceutical composition according to claim 6, wherein the coating agent is hypromellose.
  11. 11. A pharmaceutical composition according to claim 1, which is coated with at least one coating agent selected from among a cellulose derivative, a polyvinyl compound, a acrylate derivative, and saccharide.
  12. 12. A pharmaceutical composition according to claim 11, wherein the coating agent is one or more species selected from among hypromellose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol, povidone, Polyvinyl acetate, polyvinyl acetal diethylaminoacetate, aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer dispersion, sucrose, and mannitol.
  13. 13. A pharmaceutical composition according to claim 11, wherein the coating agent is one or more species selected from among a cellulose derivative and a polyvinyl compound.
  14. 14. A pharmaceutical composition according to claim 11, wherein the coating agent is one or more species selected from among hypromellose, ethyl cellulose, and polyvinyl alcohol.
  15. 15. A pharmaceutical composition according to claim 11, wherein the coating agent is hypromellose.
  16. 16. A pharmaceutical composition according to claim 6, wherein the coating agent is contained in an amount of 0.5 to 20 wt. % with respect to the total weight of the pharmaceutical composition.
  17. 17. A pharmaceutical composition according to claim 1, wherein the compound represented by formula (1) is N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide hydrochloride.
  18. 18. A pharmaceutical composition according to claim 1, wherein the compound represented by formula (1) is N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate.
  19. 19. A pharmaceutical composition according to claim 1, which has a dosage form of oral preparation.
  20. 20. A pharmaceutical composition according to claim 1, which has a dosage form of solid preparation.
  21. 21. A pharmaceutical composition according to claim 1, which has a dosage form of tablet, capsule, granule, or powder.
  22. 22. A pharmaceutical composition according to claim 1, which has a dosage form of tablet.
  23. 23. A pharmaceutical composition according to claim 1, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 6.8, of 60% or higher in 30 minutes after the start of the dissolution test and 70% or higher in 60 minutes after the start.
  24. 24. A pharmaceutical composition according to claim 1, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 6.8, of 70% or higher in 30 minutes after the start of the dissolution test and 80% or higher in 60 minutes after the start.
  25. 25. A pharmaceutical composition according to claim 1, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 4.5, of 85% or higher in 30 minutes after the start of the dissolution test.
  26. 26. A method for promoting dissolution of a compound represented by formula (1), the method employing a pharmaceutical composition as recited in claim 1.
  27. 27. A pharmaceutical composition according to claim 1, wherein dissolution of the compound represented by formula (1) serving as an active ingredient is promoted.
  28. 28. A pharmaceutical composition according to claim 6, wherein the compound represented by formula (1) is N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide hydrochloride.
  29. 29. A pharmaceutical composition according to claim 6, wherein the compound represented by formula (1) is N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate.
  30. 30. A pharmaceutical composition according to claim 6, which has a dosage form of oral preparation.
  31. 31. A pharmaceutical composition according to claim 6, which has a dosage form of solid preparation.
  32. 32. A pharmaceutical composition according to claim 6, which has a dosage form of tablet, capsule, granule, or powder.
  33. 33. A pharmaceutical composition according to claim 6, which has a dosage form of tablet.
  34. 34. A pharmaceutical composition according to claim 6, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 6.8, of 60% or higher in 30 minutes after the start of the dissolution test and 70% or higher in 60 minutes after the start.
  35. 35. A pharmaceutical composition according to claim 6, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 6.8, of 70% or higher in 30 minutes after the start of the dissolution test and 80% or higher in 60 minutes after the start.
  36. 36. A pharmaceutical composition according to claim 6, wherein, when the composition is subjected to a dissolution test by the paddle method at a rotation rate of 50 rpm, the composition exhibits an average percent dissolution of the compound represented by formula (1), in a dissolution test medium having a pH of 4.5, of 85% or higher in 30 minutes after the start of the dissolution test.
  37. 37. A method for promoting dissolution of a compound represented by formula (1), the method employing a pharmaceutical composition as recited in claim 6.
  38. 38. A pharmaceutical composition according to claim 6, wherein dissolution of the compound represented by formula (1) serving as an active ingredient is promoted.
US12569057 2007-03-29 2009-09-29 Pharmaceutical composition Abandoned US20100081685A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JPJP07-087327 2007-03-29
JP2007087327 2007-03-29
PCT/JP2008/000791 WO2008129846A1 (en) 2007-03-29 2008-03-28 Pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13968776 US9149532B2 (en) 2007-03-29 2013-08-16 Pharmaceutical composition
US14825036 US9707296B2 (en) 2007-03-29 2015-08-12 Pharmaceutical composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000791 Continuation WO2008129846A1 (en) 2007-03-29 2008-03-28 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13968776 Continuation US9149532B2 (en) 2007-03-29 2013-08-16 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
US20100081685A1 true true US20100081685A1 (en) 2010-04-01

Family

ID=39875378

Family Applications (3)

Application Number Title Priority Date Filing Date
US12569057 Abandoned US20100081685A1 (en) 2007-03-29 2009-09-29 Pharmaceutical composition
US13968776 Active US9149532B2 (en) 2007-03-29 2013-08-16 Pharmaceutical composition
US14825036 Active US9707296B2 (en) 2007-03-29 2015-08-12 Pharmaceutical composition

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13968776 Active US9149532B2 (en) 2007-03-29 2013-08-16 Pharmaceutical composition
US14825036 Active US9707296B2 (en) 2007-03-29 2015-08-12 Pharmaceutical composition

Country Status (10)

Country Link
US (3) US20100081685A1 (en)
EP (1) EP2140867B1 (en)
JP (1) JP4463875B2 (en)
KR (1) KR101424843B1 (en)
CN (2) CN101652139A (en)
CA (1) CA2680039C (en)
DK (1) DK2140867T3 (en)
ES (1) ES2644803T3 (en)
RU (1) RU2470637C2 (en)
WO (1) WO2008129846A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275666A1 (en) * 2008-12-19 2011-11-10 Daiichi Sankyo Company, Limited Activated blood coagulation factor x (fxa) inhibitor
US20130005763A1 (en) * 2010-02-22 2013-01-03 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
US8357808B2 (en) 2009-03-10 2013-01-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
WO2013026553A1 (en) * 2011-08-22 2013-02-28 Ratiopharm Gmbh Composition comprising edoxaban
US8394821B2 (en) 2009-01-13 2013-03-12 Daiichi Sankyo Company, Limited Activated blood coagulation factor inhibitor
US8404847B2 (en) 2008-12-17 2013-03-26 Daiichi Sankyo Company, Limited Method for producing diamine derivative
US8449896B2 (en) 2009-06-18 2013-05-28 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved solubility
US8541443B2 (en) 2010-03-19 2013-09-24 Daiichi Sankyo Company, Limited Crystal of diamine derivative and method of producing same
US20140171464A1 (en) * 2011-08-10 2014-06-19 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
US8901345B2 (en) 2010-07-02 2014-12-02 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
US9175012B2 (en) 2009-03-13 2015-11-03 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
US20150335579A1 (en) * 2013-01-31 2015-11-26 Sawai Pharmaceutical Co., Ltd. Multilayer tablet containing telmisartan and hydrochlorothiazide
US9629808B2 (en) 2010-02-22 2017-04-25 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
US9707296B2 (en) 2007-03-29 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition
US9918975B2 (en) 2010-03-19 2018-03-20 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5666471B2 (en) * 2009-04-30 2015-02-12 武田薬品工業株式会社 The solid preparation
EP2540317A4 (en) * 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd Sustained-release solid preparation for oral use
EP2893928A4 (en) 2012-09-03 2016-04-27 Daiichi Sankyo Co Ltd Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
JP6227352B2 (en) * 2012-09-27 2017-11-08 株式会社三和化学研究所 Anagliptin or solid preparation containing a salt thereof
EP3112371A4 (en) * 2014-02-25 2017-07-05 Daiichi Sankyo Company, Limited High-purity crystals of active blood coagulation factor x (fxa) inhibitor
JPWO2016104678A1 (en) * 2014-12-26 2017-10-12 第一三共株式会社 The pharmaceutical composition for promoting fibrinolysis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US5202129A (en) * 1989-08-04 1993-04-13 Tanabe Seiyaku Co., Ltd. Process for micronizing slightly-soluble drug
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US20020160048A1 (en) * 2001-02-15 2002-10-31 Karoline Bechtold-Peters Medical formulation containing a muscarinic agonist
US20050119486A1 (en) * 2001-06-20 2005-06-02 Toshiharu Ohta Diamine derivatives
US7081256B2 (en) * 2001-06-20 2006-07-25 Dainippon Ink And Chemicals, Inc. Quinolinone derivative pharmaceutical compositon and production method therefor
US20060275357A1 (en) * 2003-04-08 2006-12-07 Tomoyuki Oomura Organic compounds

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (en) * 1988-02-03 1998-10-22 吉富製薬株式会社 Elution of improved pharmaceutical compositions
US5149855A (en) 1989-12-26 1992-09-22 Mitsubishi Rayon Co., Ltd. Process for racemizing optically active carboxylic acid esters
US5055600A (en) 1990-04-24 1991-10-08 Rockwell International Corporation Glycidyl azide polymer (gap) synthesis by molten salt method
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
EP0638310A1 (en) 1993-08-02 1995-02-15 Bristol-Myers Squibb Company Pharmaceutical compositions containing ifetroban
US5677469A (en) 1995-05-18 1997-10-14 Sepracor, Inc. Process for resolving chiral acids with 1-aminoindan-2-ols
JPH09309829A (en) * 1996-05-22 1997-12-02 Taiyo Yakuhin Kogyo Kk Oral administration preparation containing nitrendipine and its production
JPH11180899A (en) 1997-12-15 1999-07-06 Mitsui Chem Inc Production of active methylenealkylated compound
JP3680203B2 (en) 1999-06-01 2005-08-10 東洋化成工業株式会社 Method for producing a 4-acetylamino-benzenesulfonyl azide
JP2001151724A (en) 1999-11-19 2001-06-05 Kuraray Co Ltd Method for producing optically active 2,2,4-trimethyl-3- cyclohexenecarboxylic acid
JP4044709B2 (en) * 1999-11-19 2008-02-06 信越化学工業株式会社 Aqueous film coating agent and an oral solid preparation
JP4495896B2 (en) 2000-04-05 2010-07-07 第一三共株式会社 Ethylenediamine derivatives
CN100352432C (en) * 2000-10-24 2007-12-05 味之素株式会社 Nateglinide-containing preparation
DE10106971A1 (en) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Pharmaceutical formulation containing a muscarinic agonist
RU2319699C2 (en) 2001-06-20 2008-03-20 Дайити Санкио Компани, Лимитед Derivatives of diamines
JP3939601B2 (en) * 2001-06-20 2007-07-04 株式会社アクティバスファーマ Quinolinone derivative pharmaceutical composition and a method of manufacturing the same
JP4331595B2 (en) 2001-08-09 2009-09-16 第一三共株式会社 Diamine derivative
US7342014B2 (en) 2001-06-20 2008-03-11 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
DK2258394T3 (en) * 2002-02-20 2013-08-19 Takeda Gmbh An oral dosage form comprising a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
JP4743684B2 (en) * 2002-05-22 2011-08-10 塩野義製薬株式会社 Method of improving the dissolution of a poorly water-soluble drug
KR20050110612A (en) 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 Diamine derivatives
JP4606258B2 (en) * 2003-06-17 2011-01-05 協和発酵キリン株式会社 Benidipine containing pharmaceutical compositions
CN1794993A (en) * 2003-06-17 2006-06-28 协和发酵工业株式会社 Medicinal composition containing benidipine hydrochloride
EP2266992A3 (en) 2003-11-12 2011-05-18 Daiichi Sankyo Company, Limited Process for producing thiazole derivative
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
CN102721756A (en) 2005-05-25 2012-10-10 普罗热尼奇制药公司 Synthesis of (R)-N-methylnaltrexone
ES2569398T3 (en) 2005-09-16 2016-05-10 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing same
RU2470637C2 (en) 2007-03-29 2012-12-27 Дайити Санкио Компани, Лимитед Pharmaceutical composition
WO2008156159A1 (en) 2007-06-21 2008-12-24 Daiichi Sankyo Company, Limited Process for production of diamine derivative
KR20110106840A (en) 2008-12-12 2011-09-29 다이이찌 산쿄 가부시키가이샤 Process for producing optically active carboxylic acid
JP5305421B2 (en) 2008-12-17 2013-10-02 第一三共株式会社 Method for producing a diamine derivative
ES2600783T3 (en) 2008-12-19 2017-02-10 Daiichi Sankyo Company, Limited Dosing regimen edoxaban
JPWO2010082531A1 (en) 2009-01-13 2012-07-05 第一三共株式会社 Activated blood coagulation factor inhibitor
EP2407457B1 (en) 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
CN102348680B (en) 2009-03-13 2014-11-05 第一三共株式会社 Method for producing optically active diamine derivative
WO2010131663A1 (en) 2009-05-15 2010-11-18 第一三共株式会社 Oxamide derivative
KR20120037396A (en) 2009-06-18 2012-04-19 다이이찌 산쿄 가부시키가이샤 Pharmaceutical composition having improved solubility
JP2011051672A (en) 2009-08-31 2011-03-17 Ihi Corp Rack shelf and method for assembling the same
KR101708528B1 (en) 2010-03-19 2017-02-20 다이이찌 산쿄 가부시키가이샤 Crystal of diamine derivative and method of producing same
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US5202129A (en) * 1989-08-04 1993-04-13 Tanabe Seiyaku Co., Ltd. Process for micronizing slightly-soluble drug
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US20020160048A1 (en) * 2001-02-15 2002-10-31 Karoline Bechtold-Peters Medical formulation containing a muscarinic agonist
US20050119486A1 (en) * 2001-06-20 2005-06-02 Toshiharu Ohta Diamine derivatives
US7081256B2 (en) * 2001-06-20 2006-07-25 Dainippon Ink And Chemicals, Inc. Quinolinone derivative pharmaceutical compositon and production method therefor
US20060275357A1 (en) * 2003-04-08 2006-12-07 Tomoyuki Oomura Organic compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Jacob et al, Indian Journal of Pharmaceuitcal Sciences, September 1, 2007 . *
Nassab et al "Physicochemical characterization of meloxicam-mannitol binary system", Journal of Pharmaceutical and Biomedical Analysis 41 92006) 1191-1197 *
Pharmacoat, Shin-Etsu Chemical Co., Ltd, 02/2005. *
Takeuchi et al "Tabletting of solid dispersion particles consisting of indomethacin and porous silica particles", Chem., Pharm., Bull., 53(5) 487-491 (2005). *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707296B2 (en) 2007-03-29 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition
US8404847B2 (en) 2008-12-17 2013-03-26 Daiichi Sankyo Company, Limited Method for producing diamine derivative
US20110275666A1 (en) * 2008-12-19 2011-11-10 Daiichi Sankyo Company, Limited Activated blood coagulation factor x (fxa) inhibitor
US8394821B2 (en) 2009-01-13 2013-03-12 Daiichi Sankyo Company, Limited Activated blood coagulation factor inhibitor
US8357808B2 (en) 2009-03-10 2013-01-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
US9175012B2 (en) 2009-03-13 2015-11-03 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
US8449896B2 (en) 2009-06-18 2013-05-28 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved solubility
US20130005763A1 (en) * 2010-02-22 2013-01-03 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
US9629808B2 (en) 2010-02-22 2017-04-25 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
US8541443B2 (en) 2010-03-19 2013-09-24 Daiichi Sankyo Company, Limited Crystal of diamine derivative and method of producing same
US9918975B2 (en) 2010-03-19 2018-03-20 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
US8901345B2 (en) 2010-07-02 2014-12-02 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
US9402907B2 (en) * 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
US20140171464A1 (en) * 2011-08-10 2014-06-19 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
WO2013026553A1 (en) * 2011-08-22 2013-02-28 Ratiopharm Gmbh Composition comprising edoxaban
US20150335579A1 (en) * 2013-01-31 2015-11-26 Sawai Pharmaceutical Co., Ltd. Multilayer tablet containing telmisartan and hydrochlorothiazide

Also Published As

Publication number Publication date Type
WO2008129846A1 (en) 2008-10-30 application
US9149532B2 (en) 2015-10-06 grant
EP2140867A1 (en) 2010-01-06 application
JP2010090168A (en) 2010-04-22 application
RU2470637C2 (en) 2012-12-27 grant
DK2140867T3 (en) 2017-10-09 grant
CN101652139A (en) 2010-02-17 application
ES2644803T3 (en) 2017-11-30 grant
EP2140867A4 (en) 2013-07-03 application
JP4463875B2 (en) 2010-05-19 grant
JPWO2008129846A1 (en) 2010-07-22 application
CN104324015A (en) 2015-02-04 application
KR20090122950A (en) 2009-12-01 application
CA2680039A1 (en) 2008-10-30 application
CA2680039C (en) 2015-05-26 grant
US20130337064A1 (en) 2013-12-19 application
US9707296B2 (en) 2017-07-18 grant
KR101424843B1 (en) 2014-08-13 grant
US20150342938A1 (en) 2015-12-03 application
EP2140867B1 (en) 2017-08-30 grant
RU2009139917A (en) 2011-05-10 application

Similar Documents

Publication Publication Date Title
US6306436B1 (en) Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US20050191349A1 (en) Galantamine formulations
US20070141147A1 (en) Sequential release pharmaceutical formulations
US20060193912A1 (en) Controlled release O-desmethylvenlafaxine formulations
US20080038347A1 (en) Extended release tablet formulations of flibanserin and method for manufacturing the same
EP1297836A1 (en) COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED
US5814339A (en) Film coated tablet of paracetamol and domperidone
US20050136107A1 (en) Extended release antibiotic composition
US20090208579A1 (en) Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20110218216A1 (en) Extended release pharmaceutical composition of donepezil
WO2006094737A2 (en) Gastroresistant pharmaceutical formulations containing rifaximin
US20060159753A1 (en) Matrix type sustained-release preparation containing basic drug or salt thereof
WO2013076216A1 (en) Controlled release particles comprising dimethyl fumarate
US20050181052A1 (en) Lansoprazole microtablets
US20030118647A1 (en) Extended release tablet of metformin
US7943173B2 (en) Pharmaceutical combinations of oxycodone and naloxone
US20030157169A1 (en) Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride
US20060013875A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
WO2000071099A1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
US20050244498A1 (en) Modified-release compositions of at least one form of venlafaxine
WO2009025859A1 (en) Paliperidone sustained release formulation
WO2001076557A1 (en) Sustained release preparations
US20090143404A1 (en) Pharmaceutical composition
WO2011111818A1 (en) Sustained release type pharmaceutical composition containing mosapride or salt thereof
WO2005020998A1 (en) Pharmaceutical compositions of moxifloxacin and processes for their preparation

Legal Events

Date Code Title Description
AS Assignment

Owner name: DAIICHI SANKYO COMPANY, LIMITED,JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOJIMA, MASAZUMI;KUNO, YOSHIO;NAKAGAMI, HIROAKI;AND OTHERS;SIGNING DATES FROM 20091016 TO 20091031;REEL/FRAME:023634/0957